The discovery of high affinity and metabolically stable allosteric cyclin-dependent kinase 2 (CDK2) inhibitors from screening through lead optimization

Erik B. Faber(University of Minnesota), Gunda I. Georg(University of Minnesota), Rawle Francis(University of Minnesota), Nicholas Levinson(University of Minnesota Medical Center), David J. Burban(University of Minnesota), Luxin Sun(Moffitt Cancer Center), Kwon Ho Hong(University of Minnesota), Defeng Tian(University of Minnesota), Jon E. Hawkinson(University of Minnesota), H.L.S. Wong(University of Minnesota), Kristen John(University of Minnesota), Mazen Elsaid(University of Minnesota), Liming Wang(Chinese Academy of Sciences), Nan Wang(University of Minnesota), An‐Suei Yang(Genomics Research Center, Academia Sinica), Hira Khalid(University of Minnesota), E. Schönbrunn(Moffitt Cancer Center)
ChemRxiv
August 17, 2022
Cited by 1


Related Papers